Bronstein, Gewirtz & Grossman, LLC Encourages Intellia Therapeutics, Inc. (NTLA) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...
Editas And Intellia: Strategic Shifts And Long-Term Investment Potential
A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.
bovnews5d
What’s Driving Intellia Therapeutics Inc (NTLA) Stock’s -29.00% Plunge Over the Past Month?
Intellia Therapeutics Inc (NTLA) stock saw a modest uptick, ending the day at $9.5 which represents a slight increase of $0.08 or 0.85% from the prior close of $9.42. The stock opened at $9.48 and ...
Why Is Intellia Therapeutics Stock Trading Lower On Friday?
Intellia Therapeutics Inc (NASDAQ:NTLA) outlined its strategic priorities for 2025, emphasizing the acceleration of late-stage programs for NTLA-2002 and nex-z. These therapies target hereditary ...
Intellia Therapeutics: Buying The Path To Commercialization
Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for ...
bovnews9d
What’s Fueling Intellia Therapeutics Inc (NTLA) Stock’s -53.57% Loss Below Its 200-Day SMA?
Intellia Therapeutics Inc (NTLA) stock saw a decline, ending the day at $9.42 which represents a decrease of $-0.29 or -2.99% from the prior close of $9.71. The stock opened at $9.76 and touched a low ...
Intellia Therapeutics price target lowered to $60 from $70 at Wells Fargo
Wells Fargo lowered the firm’s price target on Intellia Therapeutics (NTLA) to $60 from $70 and keeps an Overweight rating on the shares. The discontinuation of the Alpha-1 Antitrypsin Deficiency ...
Morningstar3d
Intellia Therapeutics Inc NTLA
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
JD Supra11d
The Not-So-Safe Harbor for Research Tools: Lessons From the District of Delaware
In BlueAllele Corp. v. Intellia Therapeutics, Inc., 2024 U.S. Dist. Lexis 222094 (D. Del. Dec. 9, 2024)1, the District of ...
ATTENTION Intellia Therapeutics, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESS Newswire / January 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia ...